Petragen, a biotechnology company spun out of Yale University and the NIH, is dedicated to developing novel therapies for periodontal disease. With a mission to revolutionize dental care, Petragen focuses on creating innovative treatments that address the significant unmet needs in periodontal health. The company aims to replace traditional antibiotics with more effective solutions, targeting a market that includes over 47% of adults aged 30 years and older who suffer from some form of periodontal disease.
Notable affiliations include its roots in prestigious institutions like Yale University and the NIH, which lend significant credibility and research backing. Petragen has achieved key milestones in preclinical development, positioning itself as a leader in periodontal therapeutics. The company's impact is underscored by its potential to significantly improve patient outcomes and reduce reliance on less effective traditional treatments, marking a transformative step in dental healthcare.
